Context Therapeutics Inc.

Context Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress

CTIM-76 weekly dosing at 140–280 µg in heavily pretreated PROC: 22% confirmed ORR, 56% confirmed DCR, and median PFS of 5.6 months